| Drug Type Antibody fusion proteins | 
| Synonyms ABN 202, ABN-202, ABN202 | 
| Action inhibitors, antagonists, stimulants | 
| Mechanism CLDN3 inhibitors(claudin 3 inhibitors), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), IFNβ stimulants(Interferon beta stimulants) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Colorectal Cancer | Preclinical | South Korea  | 29 Apr 2025 | |
| Colorectal Cancer | Preclinical | South Korea  | 29 Apr 2025 | |
| Biliary Tract Neoplasms | Preclinical | South Korea  | 09 Apr 2024 | |
| Biliary Tract Neoplasms | Preclinical | South Korea  | 09 Apr 2024 | |
| Triple Negative Breast Cancer | Preclinical | South Korea  | 09 Apr 2024 | |
| Triple Negative Breast Cancer | Preclinical | South Korea  | 09 Apr 2024 | |
| Bladder Cancer | Preclinical | South Korea  | 22 Mar 2024 | |
| EGFR positive non-small cell lung cancer | Preclinical | South Korea  | 04 Apr 2023 | |
| Transitional Cell Carcinoma | Preclinical | South Korea  | 04 Apr 2023 | |
| Transitional Cell Carcinoma | Preclinical | South Korea  | 04 Apr 2023 | 






